Enterprise Value

284.5M

Cash

95.94M

Avg Qtr Burn

N/A

Short % of Float

10.41%

Insider Ownership

15.12%

Institutional Own.

61.44%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NERLYNX Details
HER2-positive breast cancer

Approved

Quarterly sales

NERLYNX Details
Metastatic HER2-positive breast cancer

Approved

Quarterly sales

Alisertib Details
Cancer, Small cell lung cancer

Phase 2

Data readout

Neratinib Details
Cervical cancer, Infectious disease, Catheter related blood stream infections

Phase 2

Data readout

Neratinib Details
Lung cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 2

Update

Neratinib Details
Bile duct disease, Cancer

Phase 2

Update

Neratinib (HKI-272) + fulvestrant + trastzuzumab Details
Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain

Phase 2

Update

Alisertib (2 combo trials) Details
Breast cancer, ER+/HER2- breast cancer

Phase 2

Initiation

Alisertib+pembrolizumab Details
Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Update